Smart phone app vs standard care for breast cancer treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a smartphone-based patient management program helps women with HER2-positive breast cancer take their medication (pyrotinib) more consistently compared to usual care. It may be a good fit if you are starting or continuing pyrotinib treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have HER2-positive breast cancer confirmed by a biopsy (IHC 3+ or FISH positive).
- You are about to start or are continuing treatment with pyrotinib, either before surgery or for advanced cancer.
- You have had no more than 1 prior anti-HER2 treatment for advanced disease.
- You can use a smartphone and read independently.
- You have no history of memory or thinking problems, severe vision or hearing issues, or prior use of pyrotinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
This study tests a smartphone app that helps people with breast cancer manage chemotherapy side effects at home. If you join, the app may help you track symptoms and get better support during treatment.
This study tests a new smartphone app designed to help women with breast cancer manage their chemotherapy treatment and its side effects. It aims to see if the app is easy to use and helpful for women going through chemo for the first time.
This study tests a program called ApricityCare that uses your smartphone to help catch and manage side effects early. It is for people with cancer who are starting or continuing treatment that goes through the bloodstream.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.